Literature DB >> 18278450

Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells.

Qiong Zhou1, Yuan Su, Ming Bai.   

Abstract

In order to investigate the effect of Polo-like kinase-1 (Plk1) depletion on cell cycle progression and cell growth in lung cancer cells, a recombinant plasmid containing antisense RNA targeting Plk1 (pcDNA3-Plk1) was transfected into A549 cells by lipofectine. RT-PCR and Western-blot were used to detect the Plk1 gene expression. Cell proliferation was evaluated by direct cell counting and bromodeoxyuridine (BrdU) labeling. Cell cycle distribution and apoptosis were examined by flow cytometry, and the inhibition rate (IR) by vinorebline (NVB) was determined by MTT assay. The results showed that after transfection of pcDNA3-Plk1 into A549 cells, the expression levels of Plk1 mRNA and protein were greatly decreased. In pcDNA3-Plk1 transfected groups, abnormal morphological changes of cells and growth inhibition were observed, and the BrdU labeling index was significantly lower than in the control groups (P<0.05). Cells in pcDNA3-Plk1 transfected groups were arresed in G2/M phase and apoptosis was detectable 72 h post transfection. IR induced by vinorebline in pcDNA3-Plk1 transfected groups was significantly higher than in other groups. These data suggested that antisense RNA targeting Plk1 could suppress the Plk1 expression, and therefore, significantly inhibit cell proliferation and induce cell cycle arrest and apoptosis. Moreover, it sensitized lung cancer cells to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278450     DOI: 10.1007/s11596-008-0106-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

1.  The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase.

Authors:  A K Roshak; E A Capper; C Imburgia; J Fornwald; G Scott; L A Marshall
Journal:  Cell Signal       Date:  2000-06       Impact factor: 4.315

2.  Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion.

Authors:  M A van Vugt; V A Smits; R Klompmaker; R H Medema
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

3.  Plk1 promotes nuclear translocation of human Cdc25C during prophase.

Authors:  Fumiko Toyoshima-Morimoto; Eri Taniguchi; Eisuke Nishida
Journal:  EMBO Rep       Date:  2002-03-15       Impact factor: 8.807

Review 4.  Polo-like kinases (Plks) and cancer.

Authors:  Noriyuki Takai; Ryoji Hamanaka; Jun Yoshimatsu; Isao Miyakawa
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

5.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

6.  Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

7.  Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549).

Authors:  Michael Jung; Steven Grunberg; Cynthia Timblin; Sylke Buder-Hoffman; Pamela Vacek; Douglas J Taatjes; Brooke T Mossman
Journal:  Histochem Cell Biol       Date:  2004-01-27       Impact factor: 4.304

8.  Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.

Authors:  Kiyohiro Ando; Toshinori Ozaki; Hideki Yamamoto; Kazushige Furuya; Mitsuchika Hosoda; Syunji Hayashi; Masahiro Fukuzawa; Akira Nakagawara
Journal:  J Biol Chem       Date:  2004-03-15       Impact factor: 5.157

9.  Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis.

Authors:  Marcel A T M van Vugt; Barbara C M van de Weerdt; Gerben Vader; Hans Janssen; Jero Calafat; Rob Klompmaker; Rob M F Wolthuis; René H Medema
Journal:  J Biol Chem       Date:  2004-06-21       Impact factor: 5.157

10.  The mitotic roles of Polo-like kinase.

Authors:  M M Donaldson; A A Tavares; I M Hagan; E A Nigg; D M Glover
Journal:  J Cell Sci       Date:  2001-07       Impact factor: 5.285

View more
  3 in total

1.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

2.  Lipid metabolic pathways as lung cancer therapeutic targets: a computational study.

Authors:  Kojiro Yano
Journal:  Int J Mol Med       Date:  2011-12-30       Impact factor: 4.101

3.  The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.

Authors:  Hefei Li; Haibo Wang; Zhenqing Sun; Qiang Guo; Hongyun Shi; Youchao Jia
Journal:  Biosci Rep       Date:  2017-07-19       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.